Is Wegovy Stronger Than Saxenda — and Does That Question Have a Straightforward Answer?

What the trial data actually shows about semaglutide versus liraglutide

The clearest answer to this question comes from the phase 3 evidence. The STEP 1 trial, which enrolled adults with obesity and no type 2 diabetes, reported a mean body-weight reduction of around 14.9% over 68 weeks with semaglutide 2.4 mg, compared with 2.4% for placebo. The SCALE Obesity and Prediabetes trial for liraglutide 3 mg reported average weight loss of roughly 8% over 56 weeks in a comparable population. These trials were run separately, under different conditions and with different durations, so a strict mathematical comparison has limits. What the evidence does establish clearly is that semaglutide produces substantially greater average weight loss than liraglutide in clinical settings. The NHS medicines page for semaglutide notes that Wegovy is taken once weekly, while Saxenda (liraglutide) is a daily injection, a practical difference that matters to many people. For a broader look at how semaglutide compares with other medicines in its class, the semaglutide overview covers the mechanism and licensed uses in detail.

Neither figure is a promise of what any individual will experience. Weight-loss medicines work alongside a reduced-calorie diet and increased physical activity; results differ by starting weight, adherence, and underlying health. That context is woven into how any prescriber discusses these medicines.

Saxenda is licensed but comes with a different clinical profile

Liraglutide (Saxenda) is licensed in the UK for weight management in adults with a BMI of 30 or above, or 27 or above alongside a weight-related health condition. It is a once-daily subcutaneous injection, titrated from 0.6 mg up to 3 mg over several weeks. It has a longer track record in clinical practice than semaglutide, and for some patients with specific contraindications to semaglutide it may still be a relevant option to discuss with their prescriber. The side-effect profile is broadly similar (nausea, vomiting, diarrhoea and constipation are the most commonly reported effects) because both medicines act on the same GLP-1 receptor pathway. Where they differ is in duration of action, injection frequency and, as the trials show, average weight loss achieved. Our prescribers hear this question most weeks: people who started on Saxenda and are wondering whether switching to Wegovy makes sense. The honest answer is that switching is a clinical decision, not a self-service one, it depends on your current response, tolerability, and medical history. If you want to explore the distinction further, the detailed comparison of Saxenda and Wegovy covers the key differences clearly.

What is licensed for weight loss in the UK, and what nume offers

In the UK, two injectable weight-loss medicines currently hold NICE recommendations that influence NHS access: semaglutide (Wegovy, NICE TA875) and tirzepatide (Mounjaro, NICE TA1026). Saxenda (liraglutide) is MHRA-licensed for weight management but does not have a NICE technology appraisal recommendation for weight loss, and there is no equivalent phased NHS rollout for it. Privately, Saxenda is available through some clinics, but it is not dispensed by nume. The treatments we offer are Wegovy (injection and tablet) and Mounjaro. Mounjaro is a dual GIP and GLP-1 receptor agonist (the only medicine of its type licensed in the UK) and in the SURMOUNT-5 head-to-head trial it produced greater average weight reduction than semaglutide 2.4 mg. You can read more about how Wegovy works, or if you're curious how tirzepatide fits into the picture, the page on medicines stronger than semaglutide explains the evidence. Wegovy pricing context is set out on the Wegovy cost page if that's your next question. And if Ozempic has come up in your research, it helps to know that Ozempic and Wegovy are different products despite containing the same molecule.

How a clinical assessment shapes the decision

Reading trial statistics can make this feel like a simple league table, pick the highest number and go. In practice, a prescriber looks at more than average weight-loss figures. Your medical history, any medicines you already take, how your body has responded to previous treatments, and your preferences about injection frequency all shape which option is right for you. The same principle applies to the newer oral option: Wegovy tablets (25 mg oral semaglutide) were approved by the MHRA in June 2026, making them the first oral GLP-1 medicine licensed in the UK for weight management, with trial data reporting around 13.6% average weight loss over 64 weeks. Whether that or the injection suits you better is another clinical conversation. Our clinical team, led by our clinical pharmacist prescribers, reviews every consultation personally. There is no algorithm making that call. If you'd like to understand the full range of options, the weight-loss treatment overview sets out what is available and how the process works.